Live Breaking News & Updates on பிராந்திய பாய்ஸந் கட்டுப்பாடு மையம்

Stay updated with breaking news from பிராந்திய பாய்ஸந் கட்டுப்பாடு மையம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Insmed Presents Broad Range of Data Across Its Three Programs at the American Thoracic Society 2021 International Conference


Insmed Presents Broad Range of Data Across Its Three Programs at the American Thoracic Society 2021 International Conference
-Retrospective analysis of patients with COPD and NTM lung disease demonstrates statistically significantly higher mortality compared to patients with COPD without NTM lung disease-
-Post-hoc analysis from ARIKAYCE® (amikacin liposome inhalation suspension) clinical trials supports favorable benefit and safety profile, with a low number needed to treat (NNT) and high number needed to harm (NNH)-
News provided by
Share this article
Share this article
BRIDGEWATER, N.J., May 19, 2021 /PRNewswire/ Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported data from a total of nine posters and oral presentations across its three programs ARIKAYCE, brensocatib, and treprostinil palmitil inhalation powder (TPIP) at the virtual America ....

United States , New Jersey , Treprostinil Palmitil , Pharma Gmb , Mandy Fahey , Martina Flammer , Eleanor Barisser , Drug Administration , Prnewswire Insmed Incorporated Nasdaq , Company Annual Report On Form , Exchange Commission , Corporate Communications , Insmed Incorporated , Regional Poison Control Center , International Conference , American Thoracic Society , Chief Medical Officer , Mortality Associated , Nontuberculous Mycobacterial Lung Disease Among , Chronic Obstructive Pulmonary , Oral Title , Amikacin Liposome Inhalation Suspension , Refractory Mycobacterium , Complex Lung Disease , Number Needed , Poster Title ,

Insmed Reports First Quarter 2021 Financial Results and Provides Business Update


Insmed Reports First Quarter 2021 Financial Results and Provides Business Update
ARIKAYCE® (amikacin liposome inhalation suspension) Approved in Japan for Patients with NTM Lung Disease Caused by MAC Who Did Not Sufficiently Respond to Prior Treatment with a Multidrug Regimen
ARIKAYCE European Launch Under Way with Commercial Sales in Germany and the Netherlands
Enrollment Progresses in Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis and in Post-Marketing ARISE and ENCORE Studies of ARIKAYCE in Frontline NTM Lung Disease Caused by MAC
Treprostinil Palmitil Inhalation Powder (TPIP) Advancing to Phase 2 Development in Pulmonary Arterial Hypertension (PAH)
ARIKAYCE Total Revenue of $40.2 Million for the First Quarter 2021 ....

United States , New Jersey , Pharma Gmb , Mandy Fahey , Eleanor Barisser , Drug Administration , Corporate Developments Program , Company Annual Report On Form , Exchange Commission , Japan Ministry Of Health , Insmed Incorporated , Corporate Communications , Insmed Incorporated Nasdaq , Regional Poison Control Center , Will Lewis , Chief Executive Officer , European Commission , Investor Relations , Nebuliser Dispersion , Nebulizer System , Hypersensitivity Reactions , Fetal Toxicity , Common Adverse Reactions , Full Prescribing , Private Securities Litigation Reform Act , Annual Report ,